None of the more than 100 evaluable patients with mismatch repair deficient colon cancer have experienced disease recurrence after treatment with presurgical Opdivo plus Yervoy, according to study results.
Treatment with Calquence resulted in fewer toxicities, including atrial fibrillation, flutter and hypertension, in patients with previously treated chronic lymphocytic leukemia, compared with Imbruvica treatment, according to findings from the analysis of a phase 3 trial.